Last update Feb. 5, 2019

Teduglutide

Compatible

Safe substance and/or breastfeeding is the best option.

Teduglutida es un análogo sintético recombinante del péptido-2 similar al glucagón (GLP 2) humano natural, péptido secretado por las células L intestinales.
Aumenta el flujo sanguíneo portal e intestinal, inhibe la secreción ácida del estómago y reduce la motilidad intestinal. Promueve la reparación y el crecimiento del intestino mediante un aumento de la longitud de las vellosidades intestinales y la profundidad de las criptas (Shire 2018 y 2012, Billiauws 2017, Wilhelm 2014).
Indicado en el síndrome del intestino corto.
Administración por vía subcutánea diaria.

A fecha de última actualización no encontramos datos publicados sobre su excreción en leche materna.

Sus datos farmacocinéticos (elevado peso molecular y corta vida media) hace muy improbable su excreción en leche materna en cantidad clínicamente significativa.

Por su naturaleza proteica (es un péptido de 33 aminoácidos) es digerido e inactivado en el tracto gastrointestinal, no absorbiéndose, (biodisponibilidad oral prácticamente nula), lo que dificulta o impide el paso a plasma del lactante a partir de la leche materna ingerida, salvo en prematuros y periodo neonatal inmediato, en los que puede haber mayor permeabilidad intestinal.

Sus efectos secundarios son leves e infrecuentes (Shire 2018 y 2012, Carter 2017, Wilhelm 2014, O'Keefe 2013).

Uso aprobado a partir del año de edad con dosificación a partir de los 5 kg de peso (Carter 2017, Shire 2018 y 2012) y se está estudiando su uso en el periodo neonatal y del lactante pequeño (Lim 2016).

Alternatives

We do not have alternatives for Teduglutide since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Teduglutide is also known as


Teduglutide in other languages or writings:

Group

Teduglutide belongs to this group or family:

Tradenames

Main tradenames from several countries containing Teduglutide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 3.752 daltons
VD 0.1 l/Kg
Tmax 3 - 5 hours
T½ 1.3 - 2 hours

References

  1. Shire. Teduglutide. Drug Summary. 2018 Full text (in our servers)
  2. Billiauws L, Bataille J, Boehm V, Corcos O, Joly F. Teduglutide for treatment of adult patients with short bowel syndrome. Expert Opin Biol Ther. 2017 Abstract
  3. Carter BA, Cohran VC, Cole CR, Corkins MR, Dimmitt RA, Duggan C, Hill S, Horslen S, Lim JD, Mercer DF, Merritt RJ, Nichol PF, Sigurdsson L, Teitelbaum DH, Thompson J, Vanderpool C, Vaughan JF, Li B, Youssef NN, Venick RS, Kocoshis SA. Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome. J Pediatr. 2017 Abstract
  4. Lim DW, Wales PW, Turner JM, Bigam DL, Brubaker PL. On the horizon: trophic peptide growth factors as therapy for neonatal short bowel syndrome. Expert Opin Ther Targets. 2016 Abstract
  5. Burgos Peláez R, Cuerda Compes MC, García-Luna PP, Martínez Faedo C, Mauri Roca S, Moreno Villares JM, Virgili Casas MN, Wanden-Berghe C. Teduglutida: revisión de su uso en el síndrome de intestino corto. Nutr Hosp. 2016 Abstract
  6. Wilhelm SM, Lipari M, Kulik JK, Kale-Pradhan PB. Teduglutide for the Treatment of Short Bowel Syndrome. Ann Pharmacother. 2014 Abstract
  7. O'Keefe SJ, Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol. 2013 Abstract
  8. Shire. Teduglutida. Ficha técnica. 2012 Full text (in our servers)

Total visits

1,997

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche de México of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM